Inhibitors of B-cell receptor signaling for patients with B-cell malignancies.
about
Status of PI3K/Akt/mTOR pathway inhibitors in lymphomaEvolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent updateBendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma.Metadherin contribute to BCR signaling in chronic lymphocytic leukemiaEvaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithmsThe Role of CD44 in the Pathophysiology of Chronic Lymphocytic Leukemia.Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignanciesGene mutations and actionable genetic lesions in mantle cell lymphoma.PI3-kinase inhibitors in chronic lymphocytic leukemia.Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.Quantitative structure-activity relationship study on BTK inhibitors by modified multivariate adaptive regression spline and CoMSIA methods.Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.The clinical safety of ibrutinib in chronic lymphocytic leukemia.Ibrutinib-A double-edge sword in cancer and autoimmune disorders.The promise of the anti-idiotype concept.Combined pharmacophore, virtual screening and molecular dynamics studies to identify Bruton's tyrosine kinase inhibitors.Phenotype profiling of primary testicular diffuse large B-cell lymphomas.CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathwaTemplate-switching anchored polymerase chain reaction reliably amplifies functional lambda light chain transcripts of malignant lymphoma.A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line cheThe Role of Macrophage/B-Cell Interactions in the Pathophysiology of B-Cell Lymphomas.Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples.Angelica gigas Nakai and Decursin Downregulate Myc Expression to Promote Cell Death in B-cell Lymphoma.
P2860
Q27026544-709C7EEA-F630-4743-BA5E-6CA9CEEAE3ECQ28078869-B940B405-C987-4CF5-9AEC-6ABA5939B4B6Q33409872-630FF07A-D6D3-420A-9302-C1B928D4088BQ33583000-FED3575E-D62A-4A11-A1DB-73450FC23B87Q34617849-1D6E5748-64A0-4B4C-AD8B-E7E59F1ACE6CQ35489417-5E912E0F-25A1-4DA3-BC60-699448F685E8Q36334833-B7F14007-DF37-4CEA-9043-45AD6DDE4238Q37629080-35B9918B-ECCC-4527-839B-4F57048512EEQ38175868-7E1B6D8E-C7D9-48D5-A481-33F38044EFDDQ38240579-E7148243-C738-4678-8C37-71F98F02B801Q38444266-0B12A754-094D-42DA-8178-ECB5DD052B94Q38554422-EC29A199-08B4-40B4-86E4-BC79396E0676Q38584629-13EBC5CA-3FAE-41D6-AB29-96021018FB0CQ38585329-8815DEA3-177B-4815-A8CC-D3275D4B8F19Q42419120-B68FBA95-1753-48D7-9EA4-D3ED5C48A44DQ47205554-39AB67AC-1491-47D3-B046-E9DFB87AE0ABQ47769320-4F0748B3-EAA0-455C-B1D3-57DE79DD6997Q47898008-00EB2BA2-9A8E-481C-AC34-89441B41E4F7Q47937234-F619DD0E-371E-45ED-8D47-797B54FF71B5Q50247640-33ECF1BE-DFE5-4433-864D-1CE3783046F6Q54957513-9AFC9833-74AB-44A0-87BF-0936ED62BF4AQ55015828-E648B299-C76B-48B0-9302-FCA3415CC05AQ55713061-C6FF36EB-58AB-493A-8197-70376835B500
P2860
Inhibitors of B-cell receptor signaling for patients with B-cell malignancies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Inhibitors of B-cell receptor signaling for patients with B-cell malignancies.
@en
type
label
Inhibitors of B-cell receptor signaling for patients with B-cell malignancies.
@en
prefLabel
Inhibitors of B-cell receptor signaling for patients with B-cell malignancies.
@en
P2860
P1433
P1476
Inhibitors of B-cell receptor signaling for patients with B-cell malignancies.
@en
P2093
Michael Y Choi
Thomas J Kipps
P2860
P304
P356
10.1097/PPO.0B013E31826C5810
P577
2012-09-01T00:00:00Z